Reta-R3
LY3437943
Reta-R3 est un peptide de recherche à agonisme multi-récepteurs (GLP-1, GIP, glucagon) étudié dans la littérature préclinique en contexte métabolique. Proposé exclusivement comme réactif de recherche — non destiné à la consommation humaine ni à un usage médical.
En bref
- Classe
- Peptide agoniste multi-récepteurs
- Cibles
- GLP-1 / GIP / glucagon
- Forme
- Lyophilisée (poudre)
- Statut
- Research Use Only
Axes de recherche documentés
Bibliothèque d'études
Tous les résultats sur PubMedTriple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Jastreboff AM, et al. · The New England journal of medicine · 2023
Retatrutide-A Game Changer in Obesity Pharmacotherapy.
Katsi V, et al. · Biomolecules · 2025
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.
Drucker DJ · Diabetes care · 2024
Emerging pharmacotherapies for obesity: A systematic review.
Kokkorakis M, et al. · Pharmacological reviews · 2025
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.
Moiz A, et al. · Annals of internal medicine · 2025
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Coskun T, et al. · Cell metabolism · 2022
Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
Locatelli JC, et al. · Diabetes care · 2024
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
Giblin K, et al. · Diabetes, obesity & metabolism · 2026
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Rosenstock J, et al. · Lancet (London, England) · 2023
Gut hormones and appetite regulation.
Hong SH, et al. · Current opinion in endocrinology, diabetes, and obesity · 2024
What is the pipeline for future medications for obesity?
Melson E, et al. · International journal of obesity (2005) · 2025
Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.
Marathe SJ, et al. · npj metabolic health and disease · 2025
Résultats récupérés en direct depuis PubMed (NCBI). Littérature de recherche uniquement — aucun conseil médical.
Peptides de recherche — Research Use Only
- Non destinés à la consommation humaine
- Non destinés au diagnostic, au traitement ou à la prévention d'une maladie